Yabao and UniSA collaborate on drug discovery laboratory
Chinese pharmaceutical company Yabao Pharmaceutical and the University of South Australia (UniSA) will collaborate on the development of new cancer treatments through a co-funded drug discovery laboratory, to be led by UniSA Professor Shudong Wang.
Yabao Pharmaceutical will provide cash and in-kind contributions towards drug discovery and development at the laboratory, with potential candidates to be identified by UniSA. Yabao will have exclusive rights to develop and commercialise the drug candidates in China, while UniSA will retain rights in all other markets.
“We are thrilled to have the opportunity to work with the University of South Australia’s highly regarded scientists and laboratories to jointly find a way to develop important new treatments for cancer patients,” said Dr Peng Wang, president of R&D at Yabao Pharmaceutical, who noted that Yabao is constantly seeking to build relationships with organisations whose programs complement the company’s development and commercial capabilities.
Professor Wang, who is the head of UniSA’s Centre for Drug Discovery and Development, said she is looking forward to a productive collaboration with Yabao.
“The financial resources resulting from this agreement will help to rapidly advance our drug discovery towards clinical development — a goal we all share,” Professor Wang said.
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
